{"title":"Association Between Kita-kyushu Lung Cancer Antigen-1 Expression in Gastric Cancer and <i>Helicobacter pylori</i>-infection Status.","authors":"Nobue Futawatari, Takashi Fukuyama, Yusuke Akimoto, Junji Maehara, Daisuke Hihara, Yosuke Okamoto, Yuki Yokouchi, Kei Takahashi, Manabu Watanabe, Yoshihisa Saida","doi":"10.21873/anticanres.17541","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Kita-kyushu lung cancer antigen-1 (KK-LC-1), a cancer/testis antigen (CTA), is frequently expressed in tumor and non-tumor sites of the stomach in patients with gastric cancer (GC). Additionally, KK-LC-1 has been associated with <i>Helicobacter pylori</i> (<i>Hp</i>) infection. Currently, the association between <i>Hp</i> eradication and GC incidence is unclear. This study aimed to investigate the association between KK-LC-1 expression and <i>Hp</i> eradication in GC.</p><p><strong>Patients and methods: </strong>This study included 124 patients treated for gastric cancer. Pathological tissue from resected specimens was used to investigate KK-LC-1 expression in tumor and non-tumor sites. The association between 14 clinicopathological factors, including <i>Hp</i> infection and eradication, and KK-LC-1 expression was investigated and analyzed by Fisher's exact test and multivariable regression analysis.</p><p><strong>Results: </strong>KK-LC-1 expression rate in cancerous tissues from patients with GC was 74.2%. The expression of KK-LC-1 was associated with older age, mucosal layer depth of invasion, differentiated type, no lymph node metastasis, <i>Hp</i> eradication, previous <i>Hp</i> infection, and multiple cancers.</p><p><strong>Conclusion: </strong>KK-LC-1 expression was high in GC cases with previous Hp infection and successful eradication. KK-LC-1 expression pattern suggests that it may be associated with GC independently of <i>Hp</i> infection.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1599-1606"},"PeriodicalIF":1.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17541","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: Kita-kyushu lung cancer antigen-1 (KK-LC-1), a cancer/testis antigen (CTA), is frequently expressed in tumor and non-tumor sites of the stomach in patients with gastric cancer (GC). Additionally, KK-LC-1 has been associated with Helicobacter pylori (Hp) infection. Currently, the association between Hp eradication and GC incidence is unclear. This study aimed to investigate the association between KK-LC-1 expression and Hp eradication in GC.
Patients and methods: This study included 124 patients treated for gastric cancer. Pathological tissue from resected specimens was used to investigate KK-LC-1 expression in tumor and non-tumor sites. The association between 14 clinicopathological factors, including Hp infection and eradication, and KK-LC-1 expression was investigated and analyzed by Fisher's exact test and multivariable regression analysis.
Results: KK-LC-1 expression rate in cancerous tissues from patients with GC was 74.2%. The expression of KK-LC-1 was associated with older age, mucosal layer depth of invasion, differentiated type, no lymph node metastasis, Hp eradication, previous Hp infection, and multiple cancers.
Conclusion: KK-LC-1 expression was high in GC cases with previous Hp infection and successful eradication. KK-LC-1 expression pattern suggests that it may be associated with GC independently of Hp infection.
期刊介绍：
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
